Summary The platinum drug chemosensitivity of five human cervical squamous cell carcinoma cell lines (HX/151, HX/155, HX/156, HX/160 and HX/171) derived from previously untreated patients has been determined. Compared to our data obtained previously using human ovarian carcinoma cell lines, all five lines were relatively resistant to cisplatin, carboplatin, iproplatin and tetraplatin. One of the lines (HX/156) was exceptionally sensitive to the novel platinum (IV) ammine/amine dicarboxylates JM216 {bis-acetatoammine dichloro (cyclohexylamine) platinum (IV)) and JM221 {ammine dibutyrato dichloro (cyclohexylamine) platinum (IV)). The range in IC50 values across the five lines was approximately 2.5-fold for cisplatin, carboplatin and iproplatin, 13-fold for tetraplatin and JM216, and 25-fold for JM221. No significant correlation (P>0.05) was observed between platinum drug chemosensitivity and either glutathione levels or cadmium chloride sensitivity, an indicator of metallothionein levels. In addition, there was no significant correlation (P> 0.05) between cisplatin cytotoxicity and intracellular cisplatin accumulation or JM216 cytotoxicity and intracellular JM216 accumulation over the dose range 5 -100 JM (2 h exposure). The exceptional sensitivity of HX/156 to JM216 appears, at least partially, to be a result of enhanced accumulation of JM216.
In England and Wales the incidence of carcinoma of the cervix is 4,500 new cases per year with an overall 5 year survival rate of 58% (Cancer Research Campaign, 1992) . 95% of cervical neoplasms are derived from squamous cell, with the remainder adenocarcinomas. The disease accounts for approximately 3% of female cancer deaths. In recent years, despite an overall decrease in incidence primarily due to Papanicolaou's smear screening, there has been an apparent increase in incidence amongst younger women (<35 years) (Russell et al., 1987; Smales et al., 1987) . Whilst the prognosis for the majority of patients is good through the treatment of early stage disease by surgery and radiotherapy, there is a need for active chemotherapeutic agents for more advanced stages of the disease.
The intrinsic chemosensitivity of cervical cancer appears to be significantly less than that of ovarian cancer. Using human tumour clonogenic assays from fresh biopsies, cervical cancer in vitro drug sensitivity rates were as low as 20% for some classes of standard chemotherapeutic agents (Welander & Parker, 1987) . Cisplatin has been shown to be the most active single cytotoxic agent available for the treatment of patients presenting with recurrent or metastatic cervical cancer; no other agent has consistently shown objective response rates of greater than 25% (Alberts & Mason-Liddil, 1989; Alberts et al., 1991) . The effectiveness of cisplatinbased chemotherapy, however, is commonly limited due to both impaired drug distribution resulting from prior pelvic irradiation, and drug resistance (both intrinsic and acquired following treatment) (Alberts & Mason-Liddil, 1989; Alberts et al., 1991) . Because of these problems, the responses that are observed with cisplatin are generally only of short duration. Furthermore, as has also been observed in advanced ovarian cancer (Gore et al., 1989; Mangioni et al., 1989; Eisenhauer et al., 1990) , the recently developed cisplatin analogues, carboplatin and iproplatin, have not shown superior activity to cisplatin in randomised trials in advanced cervical cancer (McGuire et al., 1989) . Thus there remains an urgent requirement to develop more effective chemotherapeutic agents for the treatment of this disease.
Our drug discovery programme is aimed at developing novel platinum-based anticancer drugs which are capable of circumventing clinical resistance to cisplatin and carboplatin. To assist in this objective, our efforts have concentrated mainly on establishing preclinical models of intrinsic and acquired cisplatin-resistant human ovarian carcinoma (Hills et al., 1989; Harrap et al., 1990; Kelland et al., 1992a,c) . However, it may be equally important to target preclinical evaluation and mechanistic studies upon somewhat less responsive tumour types such as cervical carcinoma. To date, studies of cisplatin resistance mechanisms have focussed predominantly on tumour types such as ovarian carcinoma (Andrews et al., 1985; Behrens et al., 1987; Kuppen et al., 1988; Kikuchi et al., 1990; Kelland et al., 1992c) , testicular teratoma (Kelland et al., 1992b) and small cell lung cancer (Hospers et al., 1988) Kelley & Rozencweig, 1989; Andrews & Howell, 1990; Canon et al., 1990) .
In this present study, five cell line models of human cervical squamous cell carcinoma (all derived from previously untreated patients) have been used to determine the cytotoxic properties of the clinically available platinum-based drugs cisplatin, carboplatin, iproplatin and tetraplatin, and two novel platinum (IV) ammine/amine dicarboxylates, a class of compounds which exhibit selective cytotoxicity in intrinsically cisplatin resistant human ovarian carcinoma cell lines (Kelland et al., 1992d) . The correlation between platinum drug cytotoxicity and glutathione levels, metallothionein levels and intracellular platinum accumulation has been investigated. In addition, in one cell line, acquired resistance to cisplatin has been generated through in vitro exposure. The mechanistic basis for acquired cisplatin resistance in this cell line has been investigated. The ability of clinically available and novel platinum complexes and non-platinum anticancer drugs to circumvent this resistance has also been assessed.
Materials and methods

Cell lines
Five human cervical squamous cell carcinoma cell lines, HX/151, HX/155, HX/156, HX/160 and HX/171 were used in this study. Their establishment and biological characterisation have been described previously (Kelland et al., 1987; Kelland & Tonkin, 1989) . All five lines were derived from previously untreated patients. The cell lines grew as monolayers in Dulbecco's Modified Eagles Medium (DMEM) containing 10% foetal calf serum, 50 igml-l gentamicin, 2.5tg ml-' amphotericin B, 2mM L-glutamine, lO gml-' insulin and 0.5 lg ml-' hydrocortisone in a 10% C02, 90% air atmosphere. Cells were periodically checked and found to be free of mycoplasma and used in these studies from passage 15 to 50.
Anticancer agents and chemicals
The platinum drugs, cisplatin (cis-diamminedichloroplatinum (II)), carboplatin {cis-diammine-1, 1-cyclobutane dicarboxylatoplatinum(II)), iproplatin (CHIP, cis-dichloro-trans-dihydroxo-cis-bis (isopropylamine) platinum (IV)), JM 118 {ammine dichloro(cyclohexylamine) platinum(II)), JM 132 {ammine tetrachloro(cyclohexylamine) platinum(IV)}, JM149 famminecis-dichloro-trans dihydroxo (cyclohexylamine) platinum (IV)}, JM216 (bis-acetato-ammine dichloro (cyclohexylamine) platinum (IV)), JM221 {ammine dibutyratodichloro (cyclohexylamine) platinum (IV)) and JM244 {ammine dibenzoatodichloro (propylamine) platinum (IV)) were synthesised by and obtained from the Johnson Matthey Technology Centre (Reading, Berkshire, UK). Tetraplatin {(trans-d,l) 1,2-diaminocyclohexane tetrachloroplatinum (IV)) was kindly provided by Dr M. Wolpert-Defilippes (NCI, Bethesda, MD, USA). The structures of these agents are shown in Figure  1 .
Cadmium chloride, mitomycin C, vinblastine, chlorambucil, etoposide and sulphorhodamine B were obtained from Sigma Chemicals (Poole, UK). Cytotoxicity was assessed using the sulphorhodamine B (SRB) assay (Skehan et al., 1990) . This was performed as described previously (Mistry et al., 1991; Kelland et al., 1992d Indirect quantitation of metallothionein levels Metallothionein levels were measured indirectly by determining sensitivity of the cell lines to cadmium chloride using a 96 h continuous exposure SRB assay as described above. Resistance to cadmium chloride has been shown to be associated with elevated metallothionein levels resulting from gene amplification, increased gene transcription and increased mRNA stability (Hamer, 1986) .
Glutathione (GSH) assay Cellular GSH content was determined, in cells grown under identical conditions to those used for the assessment of cytotoxicity, as described previously (Mistry et al., 1991) . Approximately 1 x 106 cells were seeded into triplicate 25 cm2 tissue culture flasks and incubated overnight. Cells were then washed twice with 25 ml ice-cold PBS and cellular GSH extracted by a 10 min incubation at 40C with 2 ml of ice-cold 0.6% sulphosalicylic acid (SSA) with occasional shaking. Total GSH in the extract was then determined by an enzymatic assay utilising glutathione reductase (Griffiths, 1980) . Protein (precipitated by the SSA) was determined after solubilisation in 2 ml of 1 M sodium hydroxide according to Lowry et al. (1951) . The GSH content was expressed either as nmol GSH/mg protein or nmol GSH/106 cells, cell counts being carried out on parallel flasks.
Intracellular platinum accumulation
Approximately 3 x 106 cells growing exponentially in triplicate 25 cm2 tissue culture flasks were exposed to cisplatin, tetraplatin or JM216 at concentrations from 1,100 jAM for 2 h. Immediately after exposure, cells were washed three times with 25 ml ice-cold PBS, scraped and harvested in 0.5 ml PBS. Samples were then sonicated at 4°C (Soniprep 150, Fisons, Loughborough, UK) and total platinum content determined by flameless atomic absorption spectroscopy (FAAS) (Perkin Elmer model 1 lOOB and HGA700). Intracellular platinum levels were expressed as nmol Pt mg-' protein, protein content being determined from a 50 ,sl aliquot of cell sonicate (which had been digested overnight in 200 JlI of 1 M sodium hydroxide at 37C) according to Lowry et al. (1951) .
Determination ofplatinum bound to the DNA Approximately 8 x 107 cells at near confluence in 175 cm2 tissue culture flasks were exposed to cisplatin at concentrations from 10-100 JM for 2 h. Cells were harvested by trypsinisation and the DNA extracted by a modification of the method of Kirby & Cook (1967) . Cells were lysed (using 10mM Tris, 10 mM EDTA, 0.15 M NaCl and 0.4% SDS) in the presence of 1 mg ml' proteinase K for O min at 65°C, then overnight at 37°C. The DNA was then isolated following phenol extraction, ethanol precipitation, ribonuclease A treatment, re-extraction and reprecipitation. The DNA was hydrolysed in 0.5 ml 0.2% nitric acid and the platinum content of the hydrolysate determined by FAAS. DNA platination levels were expressed as nmol Pt g' DNA, the DNA content of the hydrolysate being determined from an aliquot according to Burton (1956) .
Statistical analysis Statistical significance was tested using an unpaired twotailed Student's t-test.
Results
Characterisation of the five human cervical squamous cell carcinoma cell lines Platinum drug chemosensitivity Figure 2 shows the sensitivity of HX/151, HX/155, HX/156, HX/160 and HX/171 to the clinically used platinum-based drugs cisplatin, carboplatin, iproplatin and tetraplatin, and two novel platinum (IV) ammine/amine dicarboxylates JM216 and JM221. cytotoxicity and intracellular platinum levels following cisplatin (JM216) exposure at any concentration; e.g. at 25 LM cisplatin: r = -0.65, P = 0.42; at 25gM JM216: r = -0.04, P = 0.94. Intracellular platinum levels in HX/1 51, HX/1 55, HX/156, HX/160 and HX/171 after JM216 exposure were (on average across the five concentrations used) respectively 9, 5, 17, 6 and 15-fold higher than intracellular platinum levels after cisplatin exposure; there was no significant correlation between these ratios and the ratios of JM216: cisplatin cytotoxicity in the five lines (r=0.74, P=0.15).
Derivation of acquired cisplatin resistance in HX/155
The parent HX/1 55 cell line was exposed to increasing concentrations of cisplatin from 25 nM up to a final concentration of 10 tLM over an 18 month period. Typically, the concentration was increased in 2-fold steps with three exposures at each concentration. Exposure was continuous over 3 days; the drug was then removed, and the cells were exposed again when normal growth had resumed.
The derived cell line, HX/155cisR (which has not been cloned), retained an identical morphological appearance to that of the parent line under phase contrast microscopy. In addition, there was no difference in population doubling time Non-cross resistance was defined as RF<1.5. Figure 5 shows the cross-resistance profile of HX/155cisR to 10 platinum-based drugs. HX/155cisR was 8.6-fold resistant to cisplatin. It showed cross-resistance to tetraplatin and partial cross-resistance to carboplatin, whilst iproplatin circumvented resistance. A low level of cross-resistance (RF We have attempted to determine the mechanistic basis for the resistance of HX/155cisR to cisplatin, the observed crossresistance to tetraplatin (a platinum (IV) 1,2-diaminocyclohexane (DACH) complex currently in Phase I clinical trial (Anderson et al., 1986; Christian et al., 1991) and the partial circumvention of resistance by the novel platinum (IV) ammine/amine dicarboxylate JM216 (which is currently undergoing Phase I clinical evaluation as an orally administrable drug at the Royal Marsden Hospital, Sutton). Intracellular platinum accumulation Figure 6 shows total intracellular platinum levels, expressed Resistance factor (RF) = IC50HX1 55cisR/IC30HX/l 55. In these experiments we have attempted to determine the biochemical mechanisms underlying intrinsic and acquired cisplatin resistance in human cervical squamous cell carcinoma. Acquired resistance may be the result of selection for intrinsically resistant cells and/or the result of de novo induction of resistance mechanisms. Different mechanisms may underlie intrinsic versus acquired resistance. The cytotoxicity of various platinum-based complexes has been determined in five human cervical squamous cell carcinoma cell lines. The cytotoxicity of cisplatin was similar in all five lines, with IC50 values comparable to the least sensitive cell lines from our previously described panel of human ovarian carcinoma cell lines with a 100-fold range in cisplatin sensitivity (Mistry et al., 1991; Kelland et al., 1992b) . Moreover, the lines were at least 5-fold more resistant to cisplatin than our previously described cell line (GCT27) derived from a patient presenting with testicular teratoma (Kelland et al., 1992b) . Thus the five cervical lines appear to be intrinsically resistant to cisplatin. The cytotoxicity of carboplatin and iproplatin was also similar in all five lines, whereas the cytotoxicity of tetraplatin varied by approximately 13-fold over the five lines. This correlates well with results seen for a panel of ten human ovarian carcinoma cell lines in which cisplatin, carboplatin and iproplatin elicited a very similar pattern of response whereas that of tetraplatin was completely different (Hills et al., 1989) . IC50 values for carboplatin, iproplatin and tetraplatin were all at the least sensitive end of the human ovarian carcinoma cell line range (Kelland et al., 1992d) It has previously been reported that levels of GSH, the major intracellular non-protein thiol, correlate with cisplatin, carboplatin, iproplatin and tetraplatin sensitivity in a panel of human ovarian carcinoma cell lines (Mistry et al., 1991) , and with cisplatin and iproplatin sensitivity in a series of L1210 cell lines (Hrubisko et al., 1993) . GSH levels were measured in the five cervix lines and were found to vary by 10-fold across the five lines when expressed in terms of protein content, and by 6-fold when expressed in terms of cell number, despite the fact that the sensitivity to cisplatin, carboplatin and iproplatin was similar for all five lines. Moreover, there was no significant correlation (P> 0.05) between GSH levels and the variable sensitivity of the five lines to tetraplatin, JM216 or JM221. The range of GSH levels observed in the five intrinsically cisplatin resistant cervix lines was similar to that observed in the ovarian cell line panel, which contains both intrinsically resistant and sensitive lines (Mistry et al., 1991) , and the cisplatin sensitive GCT27 human testicular tumour cell line (Kelland et al., 1992b) .
Platinum-based drugs
Levels of metallothioneins, which are composed of 30% cysteine and constitute the major fraction of intracellular protein thiols, have been shown to correlate with tetraplatin sensitivity in a series of L1210 cell lines (Hrubisko et al., 1993 (Kelland et al., 1992c) and a cisplatin sensitive human testicular tumour cell line, GCT27 (CdCl2 IC50 10.4 ,UM) (Kelland et al., 1992b) . As with GSH levels, no significant correlation (P> 0.05) was observed between cadmium chloride sensitivity and the cytotoxicity of any of the six platinum drugs investigated.
In an attempt to explain the intrinsic resistance of the five cervix lines to cisplatin and the exceptional sensitivity of HX/1 56 to the platinum (IV) ammine/amine dicarboxylates JM216 and JM221, intracellular platinum accumulation was measured in the five lines following cisplatin and JM216 exposure. Intracellular platinum levels following cisplatin exposure showed no significant correlation with cisplatin cytotoxicity (P> 0.05) and were not abnormally low compared to two cisplatin sensitive human ovarian carcinoma cell lines, CHl and 41M (Kelland et al., 1992c ) and a cisplatin sensitive human testicular tumour cell line, GCT27 (Kelland et al., 1992b) . Intracellular platinum levels after JM216 exposure showed no significant correlation with JM216 cytotoxicity (P> 0.05) and were higher at equimolar doses than those observed after cisplatin exposure in all five cell lines. The difference was greatest in HX/156, intracellular platinum levels being 17-fold higher (on average across the dose range 5-1I100M) after exposure to JM216 compared to cisplatin. This may account for the 13-fold greater sensitivity of HX/156 to JM216 compared to cisplatin. However, in HX/171, which is only 2.7-fold more sensitive to JM216 than to cisplatin, intracellular platinum levels were also much higher (15-fold) after exposure to JM216 compared to cisplatin. From these results it appears that the platinum drug sensitivity/resistance of the five cervix lines cannot be explained by one factor alone, and is probably determined by a combination of several factors such as intracellular thiol levels, intracellular platinum accumulation, DNA adduct formation and DNA repair.
To further study the mechanistic basis of cisplatin resistance in human cervical squamous cell carcinoma, an acquired resistant variant of one of the lines, HX/155, has been established by in vitro exposure to increasing concentrations of cisplatin. The derived line, HX/lSScisR, is 8.6-fold stably resistant to cisplatin and completely cross-resistant to tetraplatin, a drug which was developed for clinical trial due to the fact that it retained activity in acquired cisplatin resistant variants of murine L1210 and P388 leukaemia cell lines (Burchenal et al., 1977) . Partial cross-resistance was observed to carboplatin whereas iproplatin circumvented resistance. The novel platinum (II) ammine/amine complex JM 118 and the novel platinum (IV) ammine/amine complexes JM132, JM149, JM216, JM221 and JM244 all exhibited resistance factors of between 1.5 and 2. Complete circumvention of resistance to produce some collateral sensitivity was achieved by all the non-platinum anticancer agents examined. We have attempted to determine the mechanisms underlying acquired resistance to cisplatin and cross-resistance to tetraplatin in HX/155cisR. The mechanistic basis for the partial circumvention of resistance by 'the novel platinum (IV) ammine/amine dicarboxylate, JM216, has also been investigated.
Reduced intracellular platinum accumulation has been shown to play a major role in acquired cisplatin resistance in both human ovarian carcinoma (Andrews et al., 1988a; Hill et al., 1992; Kelland et al., 1992c) and human non-small cell lung cancer (Bungo et al., 1990) Resistance to cisplatin may also be mediated by intracellular thiols which bind to cisplatin in the cytosol to form an inactive thioether. GSH has been implicated in acquired cisplatin resistance in A2780 human ovarian carcinoma (Hamilton et al., 1985; Behrens et al., 1987; Godwin et al., 1992) and GLC4 human small cell lung carcinoma (Hospers et al., 1988) cell lines. GSH levels were found to be significantly increased in HX/155cisR compared to HX/155 by 1.3-fold when expressed in terms of protein content, and by 1.6-fold when expressed in terms of cell number. The relative importance of such elevated GSH levels in the resistance of HX/155cisR may be assessed by investigating the extent by which buthionine sulfoximine mediated GSH depletion is able to reverse the resistant phenotype (Andrews et al., 1985; Hamilton et al., 1985; Andrews et al., 1988b) . Levels of glutathione-S-transferase, which catalyses the conjugation of GSH to electrophiles, may also be elevated as has been reported previously (Teicher et al., 1987; Lewis et al., 1988; Teicher et al., 1991) . Elevated metallothionein levels have been observed in acquired cisplatin resistant variants of a number of human tumour cell lines (Kelley et al., 1988) . HX/1SScisR was 1.9-fold more resistant to cadmium chloride than the parent line, suggesting that metallothionein levels may be elevated in HX/155cisR.
There is considerable evidence that cisplatin exerts its cytotoxic effects by binding to DNA to form bidentate intrastrand and interstrand cross-links (Pinto & Lippard, 1985; Roberts et al., 1986) . After exposure of HX/155 and HX/lSScisR to cisplatin, the total amount of platinum bound to DNA was significantly reduced by 3.6-fold in HX/lSScisR. This essentially reflects a reduction in DNA intrastrand cross-links which account for the majority of platinum-DNA adducts (Roberts et al., 1986) . DNA interstrand cross-links may also be reduced in HX/1SScisR. It is possible that the elevated GSH levels in HX/lSScisR quench DNA-platinum monoadducts, preventing rearrangement to interstrand crosslinks, and so resulting in a higher proportion of platinum bound to the DNA in HX/lSScisR being in the form of monofunctional adducts (Eastman 1987; Fram et al., 1990) .
From these results it appears that the mechanism of resistance of HX/155cisR to cisplatin is multifocal, with reduced intracellular accumulation and elevated glutathione and metallothionein levels combining to reduce the amount of cisplatin binding to the DNA. However, it is possible that differeing mechanisms of resistance may have occurred through the use of alternative selection procedures as observed in another study (Andrews et al., 1989 ). An increased ability to repair cisplatin-damaged DNA, which has been demonstrated in acquired cisplatin resistant variants of several cell lines including HeLa human cervical adenocarcinoma (Chao et al., 1991) , GCT27 human testicular non seminomatous germ cell tumour (Kelland et al., 1992b) and A2780 human ovarian carcinoma (Masuda et al., 1988; Masuda et al., 1990) , cannot be ruled out. However, the complete lack of cross-resistance of HX/155cisR to other bifunctional alkylating agents such as melphalan, chloram- bucil and mitomycin C provides indirect evidence to suggest that increased DNA repair is unlikely to play a major role in the resistance. Such a multifocal resistance mechanism has previously been described in acquired cisplatin resistant sublines of human small cell and non-small cell lung carcinoma, melanoma, breast adenocarcinoma, and head and neck squamous cell carcinoma (Teicher et al., 1987; Teicher et al., 1991) . The cross-resistance of HX/155cisR to tetraplatin can be attributed to the fact that the reduction in drug accumulation by HX/155cisR is similar for both cisplatin and tetraplatin. In contrast, the novel platinum (IV) ammine/amine dicarboxylate, JM216, overcomes reduced drug accumulation by HX/155cisR and hence partially circumvents resistance. This is consistent with previous reports which have shown that platinum (IV) ammine/amine dicarboxylates can completely circumvent resistance in an acquired cisplatin resistant variant of the 41M human ovarian carcinoma cell line (41McisR) in which the major mechanism of resistance is reduced drug accumulation (Kelland et al., 1992c) . These agents are thought to overcome reduced drug accumulation by 41McisR as a result of their enhanced lipophilicity over cisplatin (Loh et al., 1992) .
In summary, HX/151, HX/155, HX/156, HX/160, HX/171 and HX/155cisR cell lines provide in vitro preclinical models of intrinsic and acquired cisplatin resistance in human cervical squamous cell carcinoma; these may have utility alongside human ovarian carcinoma models in the discovery and evaluation of novel platinum-based anticancer drugs which are able to circumvent cisplatin resistance in the clinic.
